Vemurafenib
Brand: Zelboraf (global)
Anticancer
BRAF inhibitor (V600E)
Pharmacokinetics
| Half-life | 57 hours |
| Tmax | 4 h |
| Clearance Route | hepatic |
| Active Metabolites | yes |
| Notes | Long half-life (~57h). Usually combined with Cobimetinib to reduce resistance. |
⚠️ Safety & Warnings
Severity: Moderate
Adverse Effects:
Photosensitivity, arthralgia, rash, QT prolongation
Contraindications:
Severe arrhythmia
Precautions:
Strict UV protection needed. Monitor ECG if cardiac risk.